Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Common Equity: 2012-2025

Historic Common Equity for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to -$155.8 million.

  • Ptc Therapeutics' Common Equity rose 85.23% to -$155.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.8 million, marking a year-over-year increase of 85.23%. This contributed to the annual value of -$1.1 billion for FY2024, which is 34.15% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Common Equity is -$155.8 million, which was up 24.59% from -$206.5 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Common Equity peaked at $292.6 million during Q1 2021, and registered a low of -$1.1 billion during Q4 2024.
  • For the 3-year period, Ptc Therapeutics' Common Equity averaged around -$645.5 million, with its median value being -$670.8 million (2023).
  • As far as peak fluctuations go, Ptc Therapeutics' Common Equity tumbled by 24,236.72% in 2022, and later surged by 85.23% in 2025.
  • Ptc Therapeutics' Common Equity (Quarterly) stood at $1.4 million in 2021, then slumped by 24,236.72% to -$347.1 million in 2022, then crashed by 135.84% to -$818.6 million in 2023, then tumbled by 34.15% to -$1.1 billion in 2024, then skyrocketed by 85.23% to -$155.8 million in 2025.
  • Its last three reported values are -$155.8 million in Q3 2025, -$206.5 million for Q2 2025, and -$185.8 million during Q1 2025.